PMC3985782_01
18F-FDG-PET images at relapse (a) and 507 days after RIC-HSCT (b). Multiple indications of abnormal 18F-FDG uptake (a) disappeared after RIC-HSCT.
cro-0007-0188-g01.jpg
PMC3985782_01_cro-0007-0188-g01.jpg
F1
The drug induced CR, which sustained for 23 months, but lymphoma eventually relapsed (fig. 1a). PET examination on day 80 also showed no abnormal uptake (fig. 1b).
Wright-Giemsa staining (a) and cytogenetic analysis (G banding) (b) of BM cells at the onset of t-MDS. Typical dysplastic hematopoietic cells, i.e., hypogranular neutrophils (arrowheads) and a micromegakaryocyte (arrow) were identified (a), and complex cytogenetic alterations, including chromosome 7 deletion, were detected (b).
cro-0007-0188-g02.jpg
PMC3985782_01_cro-0007-0188-g02.jpg
F2
However, myelosuppression accompanied by grade 4 neutropenia lasted for several weeks after the last dose of bendamustine, and BM analysis revealed hypocellularity with an increase in myeloblasts (5.2% of all nucleated cells) and multilineage dysplastic changes, which was documented in this case for the first time (fig. 2a). Chromosomal analysis revealed the presence of complex karyotypic abnormalities, including chromosome 7 deletion (fig. 2b).